{"id":"bromfenac-sodium-0-07","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Foreign body sensation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bromfenac sodium ophthalmic solution works by blocking COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and swelling. By reducing prostaglandin levels in ocular tissues, it decreases postoperative inflammation and pain following cataract surgery and other ocular procedures. The 0.07% formulation is a topical ophthalmic preparation applied directly to the eye surface.","oneSentence":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:46.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative inflammation and pain following cataract surgery"},{"name":"Ocular itching associated with allergic conjunctivitis"}]},"trialDetails":[{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT07090044","phase":"PHASE4","title":"Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period","status":"COMPLETED","sponsor":"Retina Research Institute, LLC","startDate":"2021-08-20","conditions":"Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema","enrollment":77},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT03751059","phase":"PHASE4","title":"NSAID vs Steroid in Trabeculectomy Wound Management","status":"UNKNOWN","sponsor":"Cindy Hutnik","startDate":"2020-11","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT03886779","phase":"PHASE4","title":"Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2013-10-30","conditions":"Treatment of Ocular Inflammation Associated With Cataract Surgery","enrollment":57},{"nctId":"NCT01847638","phase":"NA","title":"Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery","status":"COMPLETED","sponsor":"Melissa Toyos","startDate":"2013-04-01","conditions":"Cataract, Retinal Edema, Inflammation","enrollment":50},{"nctId":"NCT01367249","phase":"PHASE3","title":"Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":"Pain, Inflammation, Cataract","enrollment":440}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Bromfenac Sodium 0.07%","genericName":"Bromfenac Sodium 0.07%","companyName":"Retina Research Institute, LLC","companyId":"retina-research-institute-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative inflammation and pain following cataract surgery, Ocular itching associated with allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}